IGC

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Neurology, Mental Health, Other Science, Research, Science, Clinical Trials, Dementia, Safety, Agitation, THC, Pharma, Neuroinflammation, Cognition, Verbal aggression, Caregiver, Hospital, CB1, Behavior, IGC, Pharmaceutical industry

IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug contains THC as one of two active pharmaceutical agents.

Key Points: 
  • IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug contains THC as one of two active pharmaceutical agents.
  • IGC-AD1 is a first-of-its-kind THC-based-formulation undergoing a formal Phase 2 clinical trial in Alzheimer’s disease ( clinicaltrials.gov , Identifier: CT05543681).
  • “The interim data indicate early signs of potential clinical benefit with IGC-AD1 with infrequent treatment limiting side effects.
  • To date over 1,000 oral doses have been administered, with no dose-limiting adverse events observed, highlighting the safety profile of IGC-AD1.

IGC Pharma Adds Advisor in Artificial Intelligence

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Artificial Intelligence, Science, Clinical Trials, Diagnosis, Agitation, Biomedicine, Mathematics, Universidad, Algorithm, Biomedical engineering, Paris Dauphine University, Risk, Patient, Artificial intelligence, AI, University, Deep learning, Universidad de los Andes, Computer vision, IGC, GxP, Dementia, Medical device

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.
  • This will help IGC Pharma identify individuals who are most likely to respond to treatment and accelerate the delivery of treatments to patients.
  • Pablo Arbeláez is a distinguished researcher with over 20 years of experience in Computer Vision and Artificial Intelligence.
  • Ram Mukunda, CEO of IGC Pharma, stated, "We welcome Dr. Pablo Arbelaez to our team of Senior Advisors.

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

Retrieved on: 
Tuesday, March 26, 2024
Mental Health, Health, Neurology, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, Sale, IGC, SPA

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”), a leading asset management firm.

Key Points: 
  • IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”), a leading asset management firm.
  • The investment is for approximately $3 million in gross proceeds at the March 21, 2024, closing price of $0.34.
  • The completion of the private placement is subject to customary closing conditions, including approval by the NYSE.
  • Under the terms of the SPA, IGC will issue 8,823,529 shares of common stock.

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

Retrieved on: 
Wednesday, March 20, 2024
Women, Neurology, Cannabis, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Consumer, Health, Natural Resources, Research, IGC, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced that Ram Mukunda, CEO, and Claudia Grimaldi, Vice President, will participate in a fire chat at the BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024 ( https://www.benzinga.com/events/virtual-healthcare-summit-2024/ ).

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced that Ram Mukunda, CEO, and Claudia Grimaldi, Vice President, will participate in a fire chat at the BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024 ( https://www.benzinga.com/events/virtual-healthcare-summit-2024/ ).
  • Benzinga virtual healthcare summit 2024 will be held on March 20, 2024.
  • IGC Pharma is scheduled at 12:30 PM EDT.
  • To register for the event please see: https://www.benzinga.com/events/virtual-healthcare-summit-2024/
    Benzinga recently published an article entitled: “IGC Pharma advances in Alzheimer’s research from pre-clinical studies to phase two trial with its novel therapy candidate IGC-AD1.”
    For the full article please refer to:

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Mental Health, Other Science, Other Technology, Research, Science, Clinical Trials, Agitation, AD1, Alzheimer's disease, Patient, CMAI, IGC, AAD, Caregiver burden, Dementia, Food, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).
  • The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease, indicating strong therapeutic potential for IGC-AD1.
  • "We are excited with the positive interim results from the Phase 2 trial of IGC-AD1 for agitation in dementia due to Alzheimer's disease.
  • IGC-AD1’s interim results demonstrate a clinical and statistically significant reduction in agitation compared to placebo, suggesting a strong plausibility to address a substantial unmet medical need.

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Technology, Pharmaceutical, Mental Health, Infectious Diseases, Neurology, Artificial Intelligence, Clinical Trials, Other Technology, Science, Biotechnology, Alternative Medicine, Other Science, Health, Research, NCI, Agitation, Patient, Committee, National Cancer Institute, Virology, University, Quality of life, NIH, House, Myenteric plexus, Pancreatic Cancer Action Network, University of Maryland, Baltimore, Fetal alcohol spectrum disorder, IGC, IHV, Pharma, Jan Vansina, Bangladesh Technical Education Board, Therapy, Senate, Dementia, Public affairs, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.
  • Terry founded the Children’s Research Institute, one of America's top children’s research programs, the Pancreatic Cancer Action Network (PanCAN), and the National Organization on Fetal Alcohol Syndrome (NOFAS).
  • Ram Mukunda, CEO of IGC Pharma, commented, “With his track record of execution and extensive experience in health care, Mr. Lierman will undoubtedly bring invaluable insights and strategic guidance to IGC Pharma.
  • I look forward to collaborating with the talented team at IGC Pharma to drive forward the mission of bringing transformative therapies to patients in need.”

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acquisition, Neuropharmacology, Morris water navigation task, Dementia, Neuroscience, MWM, Amnesia, IGC, Spatial navigation, Deficit spending, Peptide, Memory, Spatial memory, Patient, LTP, Agitation, Mouse

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

Retrieved on: 
Friday, February 23, 2024
Pharmaceutical, Health, Clinical Trials, Mental Health, IGC, Pharma, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock.

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock.
  • All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma.
  • IGC is not responsible for the content, accuracy, or timelines provided by analysts.
  • By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Saturday, February 17, 2024
Science, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Mental Health, Clinical Trials, Artificial intelligence, Central nervous system disease, Pain, IGC, Loss, GMP, Composition, Treating, Cannabinoid, University, PPE, Certification, Administration, Patent, Patient, CBD, THC, LMP, Agitation, American University, Dementia, Bank statement, Somatic symptom disorder, Human, European Patent Convention, Pharmaceutical industry

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).
  • IGC is optimistic that the success in Mexico can pave the way for additional patent approvals in the U.S. and Europe.
  • We are working hard to obtain interim results in 2024.
  • With modest pricing and conservative market penetration IGC-AD1 can potentially be a block buster drug,” said Ram Mukunda, CEO of IGC Pharma.

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Retrieved on: 
Thursday, February 1, 2024
Health Technology, Technology, Cannabis, Pharmaceutical, Seniors, Artificial Intelligence, Natural Resources, Clinical Trials, Other Technology, Vitamins, Supplements, Biotechnology, Science, Other Science, Consumer, Research, Health, APP, Anxiety, Agitation, Peptide, Plaque, Machine learning, IGC, Artificial intelligence, Mouse, Dementia, Amyloid, Toxicology, Movement

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease.
  • Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models.
  • In line with IGC Pharma's artificial intelligence and machine learning ("AI/ML") initiatives, we plan to leverage cutting-edge AI/ML tools for studying TGR-63's toxicology and protein interactions.
  • The results from these multiple tests indicate that TGR-63 treatment helped normalize emotional and behavioral responses in our Alzheimer's mouse model, reinforcing its potential as a promising treatment.